NCT04618042View on ClinicalTrials.gov

FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 13, 2020

Primary Completion Date

May 14, 2021

Study Completion Date

June 13, 2021

Conditions
ArdsCovid19Pneumonia
Interventions
DRUG

FX06

FX06 i.v.: 400 mg per day (divided in two injections) during 5 days

DRUG

Placebo of FX06

Placebo i.v.: 400 mg per day (divided in two injections) during 5 days

Trial Locations (3)

49933

Service de Médecine Intensive Réanimation - CHU Angers, Angers

75013

Hôpital Pitié Salpêtrière, Paris

78240

Service de Médecine Intensive Réanimation - CHI de Poissy, Chambourcy

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04618042 - FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia | Biotech Hunter | Biotech Hunter